I have had a small position in this for awhile now and still I am impressed with their approach to diabetes. I also listened to the presentation by Sands. Nice
I have some concerns and would like your opinions. One, do you think they can hold their own with BP partnering on diabetes drugs, and more importantly the bp that is now working on a dual inhibitor. Secondly, at 2.31 pps, the market cap is large. Can Lexicon support a share price of say 5.00, when and if this comes to market. Are they overpriced or market cap too large for big Pharma to even look to acquire their product?